FINWIRES · TerminalLIVE
FINWIRES

最新消息:Keyera收購Plains All American天然氣液體資產的交易受到競爭局質疑

By

-- (第五段和第六段新增Keyera的評論;更新股票資訊。) Keyera (KEY.TO) 以51.5億美元收購Plains All American Pipeline (PAA) 加拿大天然氣液資產的交易遭遇官方阻力。加拿大競爭局週二表示,已向競爭法庭提交申請,對該交易提出質疑。 競爭局在聲明中表示,他們認為「擬議交易可能會損害天然氣液加工和儲存領域的競爭,尤其是在加拿大主要天然氣液加工和儲存樞紐——阿爾伯塔省薩斯喀徹溫堡」。 競爭局表示,向競爭法庭提交申請是基於一項調查,該調查得出結論,此次收購將消除薩斯喀徹溫堡市場的一個主要競爭對手,並加劇市場集中度。競爭局還表示,合併後的公司將「有能力提高價格、施加更不利的合約條款、減少擴大產能的激勵措施,並進一步鞏固對關鍵基礎設施的控制」。 Keyera公司去年7月首次宣布收購計畫時表示,此次收購將為其在加拿大西部和安大略省新增天然氣液分餾和加工設施,以及2,300萬桶原油儲存能力、1500英里管道和碼頭基礎設施。 Keyera在聲明中表示,週二開市前不久,公司收到了加拿大競爭局的申請。該公司稱,競爭局的質疑不會阻止其完成收購,並對相關指控表示異議。 「公司不同意競爭局局長對本次交易的斷言和描述,並將對該申請作出回應。正如公司此前所言,本次交易將加強整個盆地的競爭,並為客戶提供更便捷的關鍵市場准入渠道,以及在產品處理、運輸和銷售方面更大的靈活性。」聲明中寫道。 Keyera股票在多倫多證券交易所的最新報收在50.80加元,下跌2.17加元。

Price: $50.76, Change: $-2.21, Percent Change: -4.17%

Related Articles

Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Posco Holdings

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target price to USD94 from USD70, valuing POSCO at 0.66x 2026 P/BV, above its three-year mean of 0.52x. Our neutral view reflects: (i) recovering steel fundamentals supported by China's 2025 crude steel output declining 4.4% Y/Y and South Korea's anti-dumping duties on Chinese steel, which provides a pricing moat for Posco; and (ii) lithium market recovery with prices surging 49% YTD through April, supporting POSCO's battery materials segment which narrowed Q1 2026 losses significantly. POSCO's Australian and Argentine lithium acquisitions bolster its battery materials growth strategy. Additionally, the new Mid-term Shareholder Return Policy (2026-2028) targeting a 35%-40% payout ratio demonstrates commitment to shareholder value. However, risks include an aggressive 61% capex increase to KRW11.3 trillion in 2026, execution challenges on international projects, and persistent margin pressures. We adjust our 2026 EPS estimate to KRW6,379 from KRW5,932 and 2027 to KRW8,036 from KRW7,820.

$PKX
Research

Propel Holdings Maintained at Buy at Stifel Canada After Q1 Results; Price Target Kept at C$32.00

Stifel Canada on Tuesday reiterated its buy rating on the shares of Propel Holdings (PRL.TO) and its C$32.00 price target following the company's first-quarter results."Propel reported an upside FQ1, underscoring strength in loan growth alongside stable credit performance, on the back of the rebound in credit quality and subsequent new origination activity we saw exiting last quarter. Importantly, credit metrics PCLs and net-charge-offs normalized this quarter, supporting a recovery in ROE and fueling yet another bump in Propel's quarterly dividend (11th consecutive raise at +6.7% to $0.24/share). Net/net - results further reinforce resilience in the non-prime consumer backdrop, in-line with recent prints from US consumer credit peers. FY guide is being maintained, reaffirming the growth trajectory ahead, while suggesting some conservatism amidst the current macro uncertainty. Conference call tomorrow at 8:30am ET (dial-in: 1-888-699-1199/webcast). Our key focus on the call will be around (1) outlook for US consumer credit quality, (2) growth outlook for LaaS, (3) pace/scale of ongoing growth investments to support US expansion/Propel Bank launch," analyst Suthan Sukumar wrote.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $24.15, Change: $+2.25, Percent Change: +10.27%

$PRL.TO
Australia

Correction: BioNTech Q1 Adjusted Loss Widens, Revenue Declines; Reaffirms 2026 Revenue Outlook

(Corrects the year-ago revenue to 182.8 million euros in the third paragraph.)BioNTech (BNTX) reported a Q1 adjusted loss Tuesday of 1.95 euros ($2.28) per diluted share, widening from a loss of 1.79 euros a year earlier.Analysts polled by FactSet expected a loss of 1.27 euros.Revenue for the quarter ended March 31 was 118.1 million euros, compared with 182.8 million euros a year earlier.Analysts surveyed by FactSet expected 164.6 million euros.For 2026, the company reaffirmed revenue of between 2 billion euros and 2.30 billion euros. Analysts polled by FactSet expect 2.22 billion euros.BioNTech shares were down nearly 4.4% in Tuesday premarket activity.Price: $96.56, Change: $-2.79, Percent Change: -2.81%

$BNTX